BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Frequently asked questions
What sector does Biovie Inc (BIVI) operate in?
Biovie Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biovie Inc (BIVI) current stock price?
As of the latest data, Biovie Inc stock price is $1.29, with a previous close of $1.40. Biovie Inc lost -$0.11 in the last trading session, representing a -7.86% loss.
What is Biovie Inc (BIVI) current market capitalization?
Biovie Inc market cap is approximately 9.73 million.
What is Biovie Inc (BIVI) Earnings Per Share (EPS)?
The trailing EPS is -$3.05, and the forward EPS is -$0.63.
What is Biovie Inc (BIVI) EBITDA?
Biovie Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.21 million.
Does Biovie Inc (BIVI) pay dividends?
No. Biovie Inc does not pay a dividend.
What is Biovie Inc (BIVI) beta (volatility) score?
Biovie Inc has a beta of 0.667, indicating lower volatility than the overall market.
